Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 4043-4048

  Poelman, Susan M ^a   Adeyanju, Moses O ^c   Robertson, Maria Antonia ^c   Recant, Wendy M ^a   Karrison, Theodore ^c   Fleming, Gini F ^a   Olopade, Olufunmilayo I ^a   Conzen, Suzanne D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PROTEIN BCL 2;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CYTOTOXICITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS;

EID: 0033754958     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
2. Paclitaxel: An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers
3. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines
4. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells
5. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by Bcl-2
6. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drags and therapeutic irradiation
7. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content
8. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
9. Prognostic value of bcl-2 expression in invasive breast cancer
10. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity
11. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor positive, epidermal growth factor negative tumours and in situ cancer
12. Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study
13. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer
14. A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer
15. Inactivation of Bcl-2 by phosphorylation
16. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest
17. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein
18. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
19. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer
20. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus
21. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities
22. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers
23. BCL-2 family protein expression in human malignant glioma: A clinical-pathological correlative study
24. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol
25. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma
26. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer
27. Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas
28. p53 and Bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy
29. Pharmacodynamics of Taxol in human head and neck tumors
30. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy
31. Reduced expression of the proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
32. Nonparametric estimation from incomplete observations
33. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
34. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer in patients
35. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance
36. Expression of bcl-2 in node-negative breast cancer is associated with various prognostic factors but does not predict response to one course of perioperative chemotherapy